"Hope for Alzheimer's Patients: Breakthrough Drug Receives FDA Approval"

Two patients who participated in the clinical trials for the newly approved Alzheimer's drug, Leqembi, have shared their experiences with the medication. Joan Murtaugh, who has been receiving the drug since 2020, has seen gradual progress and maintained her daily activities without worsening symptoms. John Domeck, diagnosed with Alzheimer's at a young age, has been on the drug for four years and has experienced minimal cognitive decline. While Leqembi is not a cure, it offers hope for Alzheimer's patients by targeting the underlying disease. The drug is covered by Medicare and is most effective when combined with other treatments.